A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Crossover Study to Evaluate the Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine When Administered During the Prodrome
Latest Information Update: 23 Nov 2023
At a glance
- Drugs Ubrogepant (Primary)
- Indications Migraine
- Focus Registrational; Therapeutic Use
- Acronyms PRODROME; UBR Prodrome
- Sponsors AbbVie; Allergan
Most Recent Events
- 16 Nov 2023 Results presented in an AbbVie media release.
- 15 Nov 2023 Results published in the Lancet
- 27 Apr 2023 Primary endpoint has been met. (Percentage of Participants Reporting Absence of Headache of Moderate/Severe Intensity Within 24 Hours Post-dose)